Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells

Semin Cancer Biol. 2022 Nov;86(Pt 3):590-599. doi: 10.1016/j.semcancer.2021.09.015. Epub 2021 Oct 2.

Abstract

Cancer cells exhibit higher proliferation rates than normal cells, and as a consequence, a higher nutritional demand for metabolites such as amino acids. Such cells demonstrate high expression of amino acid transporters and are significantly dependent on the external uptake of amino acids. Moreover, some types of cancer cells exhibit oncogenic mutations that render them auxotrophic to certain amino acids. This metabolic difference between tumor and normal cells has been explored for developing anticancer drugs. Enzymes capable of depleting certain amino acids in the bloodstream can be employed to inhibit the proliferation of cancer cells and promote cell death. Certain microbial enzymes, such as l-asparaginase and l-amino acid oxidases, have been studied for this purpose. In this paper, we discuss the role of l-asparaginase, the only enzyme currently used as a chemotherapeutic agent. We also review the studies on a new potential antineoplastic agent, l-lysine α-oxidase, an enzyme of l-amino acid oxidase family.

Keywords: Amino acid metabolism; Antineoplastic enzyme; Leukemia; Trichoderma harzianum; l-lysine α-oxidase.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Oxidoreductases* / therapeutic use
  • Amino Acids / metabolism
  • Antineoplastic Agents* / therapeutic use
  • Asparaginase
  • Humans
  • Leukemia* / drug therapy
  • Leukemia* / genetics
  • Lysine

Substances

  • Amino Acids
  • Antineoplastic Agents
  • Asparaginase
  • Lysine
  • L-lysine oxidase
  • Amino Acid Oxidoreductases